Arcutis 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
31 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ivarmacitinib (SHR0302) / Jiangsu Hengrui Pharma, Arcutis
2021-001940-86: A phase 3 Study to Evaluate the Efficacy and Safety of SHR0302 in Ulcerative Colitis.

Not yet recruiting
3
368
Europe
SHR0302 tablets, SHR0302, Film-coated tablet
Reistone Biopharma Company Limited, Reistone Biopharma Company Limited
Moderately to severely active Ulcerative Colitis (UC), Ulcerative Colitis (UC), Diseases [C] - Digestive System Diseases [C06]
 
 
NCT04333771: A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis

Completed
3
566
RoW
SHR0302, Placebo
Jiangsu HengRui Medicine Co., Ltd.
Rheumatoid Arthritis
01/23
09/23
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Completed
3
336
Canada, RoW
Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2
Reistone Biopharma Company Limited
Atopic Dermatitis
08/22
05/23
NCT05470413: Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata

Active, not recruiting
3
330
RoW
SHR0302, Placebo
Reistone Biopharma Company Limited
Alopecia Areata
10/23
02/24
NCT05324631: A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Non-Radiographic Axial Spondyloarthritis

Recruiting
3
300
RoW
SHR0302, SHR0302 placebo
Jiangsu HengRui Medicine Co., Ltd.
Non-radiographic Axial Spondyloarthritis
08/24
12/24
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis

Recruiting
3
368
Europe, US, RoW
SHR0302, Placebo
Reistone Biopharma Company Limited, Reistone Biopharma Company Limited
Ulcerative Colitis
10/24
03/25
NCT04957550: To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis

Enrolling by invitation
3
444
RoW
SHR0302 tablets、Placebo, Placebo
Jiangsu HengRui Medicine Co., Ltd.
Psoriatic Arthritis
11/24
11/24
NCT04481139: A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Ankylosing Spondylitis

Completed
2/3
504
RoW
SHR0302, SHR0302 placebo
Jiangsu HengRui Medicine Co., Ltd.
Ankylosing Spondylitis
11/22
05/23
MARBLE-23, NCT04717310: Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

Active, not recruiting
2/3
645
RoW
SHR0302 Ointment, SHR0302 Ointment 2%, SHR0302 Ointment 1%, SHR0302 Ointment 0.5%, Vehicle, Placebo
Reistone Biopharma Company Limited
Atopic Dermatitis
09/23
07/24
2018-003364-31: A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.

Not yet recruiting
2
152
Europe
SHR0302, Film-coated tablet
Reistone Biopharma Company Limited, Reistone Biopharma Company Limited
Ulcerative Colitis, Ulcerative Colitis, Diseases [C] - Digestive System Diseases [C06]
 
 
2018-003303-19: A Phase II Study in Patients With Moderate to Severe Active Crohn’s Disease.

Not yet recruiting
2
144
Europe
SHR0302, Film-coated tablet
Reistone Biopharma Company Limited, Reistone Biopharma Company Limited
Crohn’s Disease, Crohn’s Disease, Diseases [C] - Digestive System Diseases [C06]
 
 
NCT06519526: Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

Recruiting
2
25
RoW
SHR-0302, SHR-2554
Fudan University
Relapsed/Refractory Peripheral T Cell Lymphoma
02/26
08/27
NCT06731153: JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Not yet recruiting
2
40
RoW
Ivarmacitinib, Camrelizumab (SHR-1210), Eribulin
Fudan University
Triple Negative Breast Cancer (TNBC), Metastatic Breast Cancer
06/27
12/27
NCT06790862: A Trial of SHR0302Base in Patients With Vitiligo

Recruiting
2
152
RoW
SHR0302Base gel, SHR0302Base gel placebo
Jiangsu HengRui Medicine Co., Ltd.
Vitiligo
03/26
04/26
NCT06925048: SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC

Not yet recruiting
2
86
NA
PD-1 inhbitor+SHR0302, PD-L1 inhibitor+SHR0302
Chunxia Su
Non-Small Cell Lung Cancer, JAK Inhibitor, Immunology
12/26
12/27
NCT04146207: SHR0302 and Steroid As First Line Therapy for Chronic GVHD

Completed
1
28
RoW
SHR0302, Prednisone
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Chronic GVHD
09/24
10/24
NCT05856058: To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability

Completed
1
16
RoW
SHR0302
Jiangsu HengRui Medicine Co., Ltd.
Graft-versus-host Disease
07/23
10/23
NCT06202612: A SHR0302 BA Study on Healthy Subjects

Completed
1
16
RoW
SHR0302 quick release tablets, SHR0302 sustained-release tablets
Jiangsu HengRui Medicine Co., Ltd.
Autoimmune Diseases
02/24
02/24
NCT05900089: Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma

Not yet recruiting
1
30
RoW
SHR0302
Henan Cancer Hospital
Peripheral T Cell Lymphoma
11/25
06/26
ChiCTR2300072447: Efficacy and safety of SHR0302 in patients with relapsed/refractory peripheral T/NK cell lymphoma

Not yet recruiting
1
30
 
Open label SHR0302 at dose A, once daily ;Open label SHR0302 at dose B, once daily ;Open label SHR0302 at dose C, once daily
Henan Cancer Hospital; Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, N/A
relapsed/refractory peripheral T/NK cell lymphoma
 
 
Zoryve foam (topical roflumilast foam) / Arcutis
2019-003354-92: A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered Daily in Adolescents and Adults with Scalp and Body Psoriasis

Not yet recruiting
2
300
Europe
ARQ-154, ARQ-154, Cutaneous foam
Arcutis Biotherapeutics, Inc., Arcutis Biotherapeutics, Inc.
Scalp and Body Plaque Psoriasis, Psoriasis (skin condition), Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
Zoryve (roflumilast cream) / Arcutis
NCT06440473: Visualization of Topical Zoryve vs. Vehicle Using Line Field Optical Coherence Tomography in Healthy Skin

Recruiting
4
3
US
Roflumilast, Vehicle (Roflumilast 0.3% vehicle cream)
Rao Dermatology
Healthy Skin
06/24
07/24
ARQ-151-315, NCT04845620 / 2021-006903-14: Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)

Hourglass Jul 2022 - Dec 2022 : Topline data from Integument-PED trial for patients aged 2-5 years old with atopic dermatitis
Completed
3
652
Canada, US
ARQ-151 Active, ARQ-151 Vehicle
Arcutis Biotherapeutics, Inc.
Atopic Dermatitis Eczema
06/23
06/23
NCT05763082: Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis

Completed
3
414
US
roflumilast cream 0.3%, Zoryve, Placebo
Padagis LLC
Plaque Psoriasis
08/23
08/23
DERMIS-OLE, NCT04286607: Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

Completed
3
333
Canada, US, RoW
Topical roflumilast, ARQ-151 Cream 0.3%
Arcutis Biotherapeutics, Inc.
Chronic Plaque Psoriasis
01/24
01/24
INTEGUMENT-OLE, NCT04804605 / 2021-006885-19: Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

Completed
3
1220
Canada, US
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%, Roflumilast
Arcutis Biotherapeutics, Inc.
Atopic Dermatitis Eczema
05/24
05/24
HDM3014-301, NCT06648772: Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study

Recruiting
3
189
RoW
Roflumilast Cream 0.3%, Zoryve, Vehicle cream
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Plaque Psoriasis
06/25
07/25
NCT06631170: Efficacy and Safety of Roflumilast Cream in Subjects with Atopic Dermatitis

Recruiting
3
351
RoW
Roflumilast Cream 0.15%, Vehicle cream
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Atopic Dermatitis (AD)
08/25
08/25
NCT05278624: Evaluation of the Safety and Efficacy of Topical Roflumilast Cream in the Treatment of Facial Papulopustular Rosacea

Completed
2
40
US
Roflumilast Cream
Dermatology Consulting Services, PLLC
Rosacea
02/23
02/23
NCT06998056: Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

Recruiting
2
100
Canada, US
ARQ-151 cream 0.05%
Arcutis Biotherapeutics, Inc.
Atopic Dermatitis (Eczema)
06/26
06/26
NCT04156191: Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema

Completed
1
101
US
ARQ-151 cream 0.15%, ARQ-151 cream 0.05%
Arcutis Biotherapeutics, Inc.
Atopic Dermatitis (Eczema)
05/23
05/23
ivarmacitinib cream (ARQ-252) / Arcutis
No trials found
ivarmacitinib topical suspension (ARQ-255) / Arcutis
No trials found
ARQ-234 / Arcutis
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ivarmacitinib (SHR0302) / Jiangsu Hengrui Pharma, Arcutis
2021-001940-86: A phase 3 Study to Evaluate the Efficacy and Safety of SHR0302 in Ulcerative Colitis.

Not yet recruiting
3
368
Europe
SHR0302 tablets, SHR0302, Film-coated tablet
Reistone Biopharma Company Limited, Reistone Biopharma Company Limited
Moderately to severely active Ulcerative Colitis (UC), Ulcerative Colitis (UC), Diseases [C] - Digestive System Diseases [C06]
 
 
NCT04333771: A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis

Completed
3
566
RoW
SHR0302, Placebo
Jiangsu HengRui Medicine Co., Ltd.
Rheumatoid Arthritis
01/23
09/23
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Completed
3
336
Canada, RoW
Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2
Reistone Biopharma Company Limited
Atopic Dermatitis
08/22
05/23
NCT05470413: Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata

Active, not recruiting
3
330
RoW
SHR0302, Placebo
Reistone Biopharma Company Limited
Alopecia Areata
10/23
02/24
NCT05324631: A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Non-Radiographic Axial Spondyloarthritis

Recruiting
3
300
RoW
SHR0302, SHR0302 placebo
Jiangsu HengRui Medicine Co., Ltd.
Non-radiographic Axial Spondyloarthritis
08/24
12/24
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis

Recruiting
3
368
Europe, US, RoW
SHR0302, Placebo
Reistone Biopharma Company Limited, Reistone Biopharma Company Limited
Ulcerative Colitis
10/24
03/25
NCT04957550: To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis

Enrolling by invitation
3
444
RoW
SHR0302 tablets、Placebo, Placebo
Jiangsu HengRui Medicine Co., Ltd.
Psoriatic Arthritis
11/24
11/24
NCT04481139: A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Ankylosing Spondylitis

Completed
2/3
504
RoW
SHR0302, SHR0302 placebo
Jiangsu HengRui Medicine Co., Ltd.
Ankylosing Spondylitis
11/22
05/23
MARBLE-23, NCT04717310: Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

Active, not recruiting
2/3
645
RoW
SHR0302 Ointment, SHR0302 Ointment 2%, SHR0302 Ointment 1%, SHR0302 Ointment 0.5%, Vehicle, Placebo
Reistone Biopharma Company Limited
Atopic Dermatitis
09/23
07/24
2018-003364-31: A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.

Not yet recruiting
2
152
Europe
SHR0302, Film-coated tablet
Reistone Biopharma Company Limited, Reistone Biopharma Company Limited
Ulcerative Colitis, Ulcerative Colitis, Diseases [C] - Digestive System Diseases [C06]
 
 
2018-003303-19: A Phase II Study in Patients With Moderate to Severe Active Crohn’s Disease.

Not yet recruiting
2
144
Europe
SHR0302, Film-coated tablet
Reistone Biopharma Company Limited, Reistone Biopharma Company Limited
Crohn’s Disease, Crohn’s Disease, Diseases [C] - Digestive System Diseases [C06]
 
 
NCT06519526: Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

Recruiting
2
25
RoW
SHR-0302, SHR-2554
Fudan University
Relapsed/Refractory Peripheral T Cell Lymphoma
02/26
08/27
NCT06731153: JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Not yet recruiting
2
40
RoW
Ivarmacitinib, Camrelizumab (SHR-1210), Eribulin
Fudan University
Triple Negative Breast Cancer (TNBC), Metastatic Breast Cancer
06/27
12/27
NCT06790862: A Trial of SHR0302Base in Patients With Vitiligo

Recruiting
2
152
RoW
SHR0302Base gel, SHR0302Base gel placebo
Jiangsu HengRui Medicine Co., Ltd.
Vitiligo
03/26
04/26
NCT06925048: SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC

Not yet recruiting
2
86
NA
PD-1 inhbitor+SHR0302, PD-L1 inhibitor+SHR0302
Chunxia Su
Non-Small Cell Lung Cancer, JAK Inhibitor, Immunology
12/26
12/27
NCT04146207: SHR0302 and Steroid As First Line Therapy for Chronic GVHD

Completed
1
28
RoW
SHR0302, Prednisone
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Chronic GVHD
09/24
10/24
NCT05856058: To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability

Completed
1
16
RoW
SHR0302
Jiangsu HengRui Medicine Co., Ltd.
Graft-versus-host Disease
07/23
10/23
NCT06202612: A SHR0302 BA Study on Healthy Subjects

Completed
1
16
RoW
SHR0302 quick release tablets, SHR0302 sustained-release tablets
Jiangsu HengRui Medicine Co., Ltd.
Autoimmune Diseases
02/24
02/24
NCT05900089: Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma

Not yet recruiting
1
30
RoW
SHR0302
Henan Cancer Hospital
Peripheral T Cell Lymphoma
11/25
06/26
ChiCTR2300072447: Efficacy and safety of SHR0302 in patients with relapsed/refractory peripheral T/NK cell lymphoma

Not yet recruiting
1
30
 
Open label SHR0302 at dose A, once daily ;Open label SHR0302 at dose B, once daily ;Open label SHR0302 at dose C, once daily
Henan Cancer Hospital; Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, N/A
relapsed/refractory peripheral T/NK cell lymphoma
 
 
Zoryve foam (topical roflumilast foam) / Arcutis
2019-003354-92: A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered Daily in Adolescents and Adults with Scalp and Body Psoriasis

Not yet recruiting
2
300
Europe
ARQ-154, ARQ-154, Cutaneous foam
Arcutis Biotherapeutics, Inc., Arcutis Biotherapeutics, Inc.
Scalp and Body Plaque Psoriasis, Psoriasis (skin condition), Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
Zoryve (roflumilast cream) / Arcutis
NCT06440473: Visualization of Topical Zoryve vs. Vehicle Using Line Field Optical Coherence Tomography in Healthy Skin

Recruiting
4
3
US
Roflumilast, Vehicle (Roflumilast 0.3% vehicle cream)
Rao Dermatology
Healthy Skin
06/24
07/24
ARQ-151-315, NCT04845620 / 2021-006903-14: Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)

Hourglass Jul 2022 - Dec 2022 : Topline data from Integument-PED trial for patients aged 2-5 years old with atopic dermatitis
Completed
3
652
Canada, US
ARQ-151 Active, ARQ-151 Vehicle
Arcutis Biotherapeutics, Inc.
Atopic Dermatitis Eczema
06/23
06/23
NCT05763082: Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis

Completed
3
414
US
roflumilast cream 0.3%, Zoryve, Placebo
Padagis LLC
Plaque Psoriasis
08/23
08/23
DERMIS-OLE, NCT04286607: Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

Completed
3
333
Canada, US, RoW
Topical roflumilast, ARQ-151 Cream 0.3%
Arcutis Biotherapeutics, Inc.
Chronic Plaque Psoriasis
01/24
01/24
INTEGUMENT-OLE, NCT04804605 / 2021-006885-19: Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

Completed
3
1220
Canada, US
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%, Roflumilast
Arcutis Biotherapeutics, Inc.
Atopic Dermatitis Eczema
05/24
05/24
HDM3014-301, NCT06648772: Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study

Recruiting
3
189
RoW
Roflumilast Cream 0.3%, Zoryve, Vehicle cream
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Plaque Psoriasis
06/25
07/25
NCT06631170: Efficacy and Safety of Roflumilast Cream in Subjects with Atopic Dermatitis

Recruiting
3
351
RoW
Roflumilast Cream 0.15%, Vehicle cream
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Atopic Dermatitis (AD)
08/25
08/25
NCT05278624: Evaluation of the Safety and Efficacy of Topical Roflumilast Cream in the Treatment of Facial Papulopustular Rosacea

Completed
2
40
US
Roflumilast Cream
Dermatology Consulting Services, PLLC
Rosacea
02/23
02/23
NCT06998056: Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

Recruiting
2
100
Canada, US
ARQ-151 cream 0.05%
Arcutis Biotherapeutics, Inc.
Atopic Dermatitis (Eczema)
06/26
06/26
NCT04156191: Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema

Completed
1
101
US
ARQ-151 cream 0.15%, ARQ-151 cream 0.05%
Arcutis Biotherapeutics, Inc.
Atopic Dermatitis (Eczema)
05/23
05/23
ivarmacitinib cream (ARQ-252) / Arcutis
No trials found
ivarmacitinib topical suspension (ARQ-255) / Arcutis
No trials found
ARQ-234 / Arcutis
No trials found

Download Options